...
首页> 外文期刊>Journal of ocular pharmacology and therapeutics: The official journal of the Association for Ocular Pharmacology and Therapeutics >Comparison of the effects of brimonidine 0.2% and timolol 0.5% on retinal nerve fiber layer thickness in ocular hypertensive patients: a prospective, unmasked study.
【24h】

Comparison of the effects of brimonidine 0.2% and timolol 0.5% on retinal nerve fiber layer thickness in ocular hypertensive patients: a prospective, unmasked study.

机译:比较0.2%溴莫尼定和0.5%替莫洛尔对高眼压患者视网膜神经纤维层厚度的影响:一项前瞻性,未公开的研究。

获取原文
获取原文并翻译 | 示例

摘要

AIMS: The aim of this study was to compare the effects of brimonidine and timolol on retinal nerve fiber layer (RNFL) thickness in ocular hypertensive patients. METHODS: This was a prospective, comparative, and unmasked study. For 12 months, 38 eyes of 19 patients with primary open-angle glaucoma received brimonidine tartrate 0.2%, and 40 eyes of 20 patients received timolol maleate 0.5%. Intraocular pressure (IOP) was measured every 2 months, and RNFL thickness was assessed using Scanning laser polarimetry (GDx) at baseline and at 12 months. RESULTS: Mean IOP reduction was similar in both groups. Within each treatment group, the RNFL thickness for ellipse average (P = 0.004), superior (P = 0.035), temporal (P = 0.003), inferior (P < 0.0001), and nasal averages (P = 0.044) were significantly decreased from baseline in timolol at 12 months. However, the RNFL thickness for ellipse average and four quadrants showed no significant change from baseline in brimonidine. The between-group difference in RNFL change showed a significant reduction for ellipse average (P = 0.02), temporal (P = 0.005), and inferior averages (P = 0.016) following timolol therapy, as compared to brimonidine. CONCLUSIONS: There appear to be less progression for RNFL damage following brimonidine 0.2% therapy compared to timolol 0.5% in ocular hypertensive patients over 1 year. This finding does not correlate with IOP reduction.
机译:目的:本研究的目的是比较溴莫尼定和噻吗洛尔对高眼压患者视网膜神经纤维层(RNFL)厚度的影响。方法:这是一项前瞻性,比较性和隐蔽性研究。在12个月中,19例原发性开角型青光眼患者的38眼接受了0.2%酒石酸溴莫尼定的治疗,20例患者的40眼接受了0.5%的马来酸替莫洛尔的治疗。每2个月测量一次眼内压(IOP),并在基线和第12个月使用扫描激光极化仪(GDx)评估RNFL厚度。结果:两组平均眼压降低相似。在每个治疗组中,椭圆平均(P = 0.004),上(P = 0.035),颞侧(P = 0.003),下(P <0.0001)和鼻平均(P = 0.044)的RNFL厚度从12个月时使用替莫洛尔治疗的基线。但是,椭圆平均和四个象限的RNFL厚度显示溴莫尼定与基线相比无明显变化。与溴莫尼定相比,噻吗洛尔治疗后,RNFL变化的组间差异显示椭圆平均(P = 0.02),时间平均(P = 0.005)和次平均(P = 0.016)显着降低。结论:在1年以上的眼压性高血压患者中,溴莫尼定0.2%治疗后RNFL损害的进展似乎少于噻吗洛尔0.5%。这一发现与降低眼压无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号